Clinical Trials Logo

Muscle Spasticity clinical trials

View clinical trials related to Muscle Spasticity.

Filter by:

NCT ID: NCT00651729 Completed - Stroke Clinical Trials

Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity

NCT ID: NCT00651690 Completed - Stroke Clinical Trials

Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment

Start date: March 2004
Phase: Phase 2
Study type: Interventional

This study evaluates the responsiveness of 7 functional tasks to botulinum toxin Type A treatment in poststroke patients with spasticity of the upper-limb flexors

NCT ID: NCT00632528 Completed - Cerebral Palsy Clinical Trials

MEOPA to Improve Physical Therapy Results After Multilevel Surgery

KINOPA
Start date: March 2008
Phase: Phase 3
Study type: Interventional

Children with cerebral palsy commonly undergo "multilevel surgery", meaning several lower limb combined procedures performed during the same surgical intervention. The aim of this type of surgery is to correct all deformities together in order to restore near to normal anatomy and muscular function. It is very important to be able to obtain good range of motion after surgery, in order to consolidate surgical results. During the first days after the operation, children are sore and it may be difficult to realize adequate physical therapy. In order to palliate this situation, MEOPA gaz is used during REHAB sessions. Good results have been obtained so far but no study is available to demonstrate these results. The goal of our research is to prove that there is a benefit in using MEOPA postoperatively in these patients.

NCT ID: NCT00623376 Completed - Clinical trials for Spasticity in Spinal Cord Injured Persons

Randomized Double Blind Cross Over Study for Nabilone in Spasticity in Spinal Cord Injury Persons

Start date: July 2007
Phase: Phase 2
Study type: Interventional

Objectives: To determine whether nabilone, a synthetic cannabinoid, alleviates spasticity in people with spinal cord injury (SCI). Methods: Twelve subjects were enrolled in this double-blind, placebo-controlled, crossover study. They received either nabilone or placebo during the first four-week period (0.5mg OD with option to increase to 0.5mg BID), then outcome measures were assessed. After a two-week washout, subjects were crossed-over to the opposite arm. The primary outcome was the Ashworth scale for spasticity in the most involved muscle group, chosen by the subject and clinician. The secondary outcomes included Spasm Frequency Scale, Visual Analog Scale, Wartenberg Pendulum Test, sum of the Ashworth Scale in eight muscle groups of each side of the body, and the Clinician's and Subject's Global Impression of Change .

NCT ID: NCT00607542 Completed - Cerebral Palsy Clinical Trials

Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity

Best PK/PD
Start date: November 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Oral baclofen is used commonly to treat spasticity in children with cerebral palsy. Although for adults there is dosing,safety and efficacy information in the package insert, this is not the case for children. The purpose of this study is to determine how fast the drug is cleared from the body, the correct dose, and long-term safety and efficacy for children with spasticity.

NCT ID: NCT00575536 Completed - Spasticity Clinical Trials

Optical Stimulation in Peripheral Nerves for Select Rhizotomy Procedures

Rhizotomy
Start date: January 2006
Phase:
Study type: Observational

The purpose of this study is to determine the safe and effective levels of optical stimulation in peripheral nerves of humans otherwise undergoing nerve lesioning in surgery.

NCT ID: NCT00557973 Completed - Muscle Spasticity Clinical Trials

A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of treatment with XP19986 Sustained Release (SR) Tablet compared to placebo in subjects with spasticity due to spinal cord injury

NCT ID: NCT00549783 Completed - Muscle Spasticity Clinical Trials

BOTOX® Economic Spasticity Trial (BEST)

Start date: October 2007
Phase: Phase 4
Study type: Interventional

This is a study to investigate if patients who have had a stroke and suffer from spasticity might benefit from being given BOTOX® in addition to the normal Standard Care. Spasticity is characterized by stiffness or frequent cramps accompanied by pain and abnormal movements and can prevent the carrying out of everyday tasks such as walking and getting dressed. BOTOX® is a neurotoxin, which is used to prevent the contraction of muscle fibre and has been shown to reduce spasticity significantly. Patients will be enrolled in this study at about 33 locations in Europe and Canada. Study participation will last for about 1 year.

NCT ID: NCT00535938 Completed - Muscle Spasticity Clinical Trials

MDs on Botox Utility (MOBILITY)

Start date: September 2007
Phase: N/A
Study type: Observational

The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.

NCT ID: NCT00488839 Completed - Multiple Sclerosis Clinical Trials

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Start date: June 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on spasticity. Lastly, this study will determine how long IPX056 affects spasticity.